Manuel Ruíz‐Borrego

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

J.F.R. Robertson, Igor Bondarenko, Ekaterina Trishkina et al. · The Lancet · 2016 · 580 citations · Full text

Mg Versus, Breast Oncology, Oncology +8

Targeting stromal remodeling and cancer stem cell plasticity overcomes chemoresistance in triple negative breast cancer

Aurélie Cazet, Mun N. Hui, Benjamin Elsworth et al. · Nature Communications · 2018 · 430 citations · Full text

Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

Hope S. Rugo, Florence Lerebours, Eva Ciruelos et al. · The Lancet Oncology · 2021 · 340 citations

Breast Oncology, Oncology, Medicine +9

PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers

Roy R. L. Bastien, Álvaro Rodríguez-Lescure, Mark Ebbert et al. · BMC Medical Genomics · 2012 · 336 citations · Full text

Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study

Erica L. Mayer, Amylou C. Dueck, Miguel Martín et al. · The Lancet Oncology · 2021 · 250 citations

Interim Analysis, Endocrine Oncology, Breast Oncology +9